



Universiteit
Leiden
The Netherlands

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

Ouwerkerk, L. van; Verschueren, P.; Boers, M.; Emery, P.; Jong, P.H.P. de; Landewé, R.B.M.; ... ; Bergstra, S.A.

Citation

Ouwerkerk, L. van, Verschueren, P., Boers, M., Emery, P., Jong, P. H. P. de, Landewé, R. B. M., ... Bergstra, S. A. (2023). Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? *Annals Of The Rheumatic Diseases*, 83, 65-71.
doi:10.1136/ard-2023-224270

Version: Publisher's Version







License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3764296>

Note: To cite this publication please use the final published version (if applicable).

CLINICAL SCIENCE

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

Lotte van Ouwerkerk ¹, Patrick Verschueren ², Maarten Boers ³, Paul Emery ⁴, Pascal Hendrik Pieter de Jong ⁵, Robert BM Landewé ^{3,6}, Willem Lems ^{3,7}, Josef S Smolen,⁸ Tom WJ Huizinga ¹, Cornelia F Allaart,¹ Sytske Anne Bergstra ¹

Handling editor Kimme L Hyrich

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ard-2023-224270>).

¹Rheumatology, Leiden Universitair Medisch Centrum, Leiden, The Netherlands

²Rheumatology, KU Leuven University Hospitals Leuven, Leuven, Belgium

³Rheumatology, Amsterdam UMC, Amsterdam, The Netherlands

⁴Rheumatology, University of Leeds Faculty of Medicine and Health, Leeds, UK

⁵Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands

⁶Rheumatology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands

⁷Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands

⁸Rheumatology, Medical University of Vienna, Wien, Austria

Correspondence to

Sytske Anne Bergstra, Department of rheumatology, Leiden University Medical Center, Leiden, Netherlands; s.a.bergstra@lumc.nl

Received 7 April 2023
Accepted 2 August 2023
Published Online First
22 August 2023



© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: van Ouwerkerk L, Verschueren P, Boers M, et al. *Ann Rheum Dis* 2024;**83**:65–71.

ABSTRACT

Objectives To compare the use of glucocorticoids (GC) over time in patients with rheumatoid arthritis (RA) who were or were not treated initially with GC bridging therapy.

Methods Data from the BeSt, CareRA and COBRA trials were combined in an individual patient data (IPD) meta-analysis. We compared GC use between bridgers and non-bridgers at 12, 18 and 24 months from baseline with mixed-effects regression analysis. Secondary outcomes were mean cumulative GC dose until 24 months after baseline with and without the bridging period, Disease Activity Score based on 28 joints (DAS28) over time and number of disease-modifying antirheumatic drug (DMARD) changes.

Results 252/625 patients (40%) were randomised to GC bridging (bridgers). Excluding the period of bridging, later GC use was low in both groups and cumulative doses were similar. Mean DAS28 was similar between the groups, but bridgers improved more rapidly ($p < 0.001$) in the first 6 months and the bridgers required significantly fewer changes in DMARDs (incidence rate ratio 0.59 (95% CI 0.38 to 0.94)). GC use was higher in the bridgers at $t = 12$ months (OR 3.27 (95% CI 1.06 to 10.08)) and the bridging schedules resulted in a difference in cumulative GC dose of 2406 mg (95% CI 1403 to 3408) over 24 months.

Conclusion In randomised trials comparing GC bridging and no GC bridging, bridgers had a more rapid clinical improvement, fewer DMARD changes and similar late use of GC compared with non-bridgers. GC bridging per protocol resulted, as could be expected, in a higher cumulative GC dose over 2 years.

INTRODUCTION

It has been extensively shown that glucocorticoids (GC) are effective as initial bridging treatment of rheumatoid arthritis (RA) by rapidly suppressing inflammation. This results in early functional improvement assessed by the Health Assessment Questionnaire) through relief of clinical symptoms,^{1–4} and prevention of joint damage progression in the long term.^{5–7} Hence, they are now often part of the initial treatment strategy in patients with early RA. However, observational studies suggest GC have significant safety issues if used long term, especially when used in higher doses.⁸ Therefore, the 2022 updated EULAR recommendations state that only short-term GC bridging therapy should be considered in the treatment of patients with early RA, without specifying the route or dose.⁹ On

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Glucocorticoids (GC) bridging is commonly used (and recommended by EULAR) as bridging therapy in the treatment of newly diagnosed rheumatoid arthritis because of its rapid effect on suppression of inflammation and damage progression and improvement of physical functioning.
- ⇒ The American College of Rheumatology 2021 updated guidelines expressed concerns about the difficulty to taper and discontinue GC after their use as bridging therapy, which might lead to unwanted prolonged GC use.
- ⇒ Previous research showed that the probability of GC use after their use as bridging therapy is low and decreasing over time.
- ⇒ Furthermore, there are some indications that patients starting with initial GC bridging (bridgers) might need less GC over time compared with non-bridgers.

WHAT THIS STUDY ADDS

- ⇒ This individual patient data meta-analysis with data from three randomised clinical trials showed that from 12 months onwards, the odds to use GC after the intended bridging period was not significantly different between an initial GC bridging group and a non-GC bridging group.
- ⇒ Furthermore, except for the initial bridging period, the cumulative dose of oral GC after bridging did not differ significantly between the groups.
- ⇒ Patients in the GC bridging group did have less disease-modifying antirheumatic drug changes compared with the non-GC bridging group and a more rapid DAS28 improvement in the first 6 months.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study emphasises the benefits of GC bridging therapy and shows that bridgers are not using more GC after their intended bridging period compared with non-bridgers during 2-year follow-up.

the other hand, in the 2021 updated American College of Rheumatology (ACR) guidelines it is stated that the toxicity associated with GC use may outweigh its known benefits.¹⁰ Consequently, in these guidelines it is advised not to start GC bridging therapy at all, although the advice has a low level of evidence and is ‘conditional’, as the expert panel acknowledge that GC bridging may often be necessary. Furthermore, the ACR panel state in their discussion that these recommendations against the use of GC were made in consideration of the difficulty to taper GC once they are started, leading to unwanted prolonged GC use. In our individual patient data (IPD) meta-analysis, we showed that in clinical trial patients treated with GC bridging therapy the rates of subsequent ongoing GC use are low and decreasing over time.¹¹ Thus, we did not find evidence that GC bridging is associated with unwanted prolonged use.

It is now of interest to know whether and how initial GC bridging is associated with later GC use and other treatment steps in the disease course, compared with not starting initial GC bridging. In two previous studies, it was suggested that patients who had started GC bridging (bridgers) needed less steroids after bridging therapy had ended, to keep their disease activity under control compared with the patients that had not started with GC bridging therapy (non-bridgers).^{12 13} To be able to analyse this in randomised clinical trials (RCTs) with larger numbers, we selected studies with at least one study arm that started initial GC bridging therapy and one that did not start initial GC bridging therapy out of the group of identified clinical trials from our systematic literature review (SLR).¹⁴ We used IPD that was collected during the first 2 years of follow-up in these RCTs.

METHODS

Ten clinical trials were identified with the SLR, and we received IPD from seven of them. We combined IPD from the three studies (BeSt, COBRA and CareRA^{1 2 15}) that had randomised patients to at least one study arm that started with GC bridging next to one or multiple conventional synthetic disease-modifying antirheumatic drug (csDMARD), as well as one arm that did not start with GC bridging (comparator arms) next to csDMARD therapy. From the CareRA study, we only included the patients with a ‘low risk for a bad prognosis’ as the ‘high-risk’ study population did not have a comparator study arm without GC bridging.

The data collection process is described in the supplementary file. Of the three study arms that started with initial GC bridging, one also started with methotrexate (MTX) as initial DMARD and two arms started with MTX plus sulfasalazine (SSZ). In the GC bridging study arms, all patients had to taper GC, with a protocolised stop 34–36 weeks after baseline (table 1), which was dependent on disease activity levels in BeSt and CareRA. The starting dose of GC bridging in both the BeSt and COBRA

bridging arms was 60 mg/day, whereas the CareRA bridging arm started with 30 mg/day. In the four comparator study arms, DMARD therapy was started without GC bridging, either with SSZ monotherapy (COBRA) or with MTX monotherapy (BeSt and CareRA). In all study arms, different DMARD options were protocolised if the first treatment step failed (online supplemental table 1). No study on GC bridging with lower doses of GC than 30 mg, a shorter bridging period than 34 weeks or a single intravenous or intramuscular application comparing with csDMARD monotherapy with IPD was available. Neither patients nor public representatives were involved in design, conduct, reporting or dissemination of this project.

Outcome measures

As primary outcome, we compared oral GC use between the groups (patients starting with GC bridging and patients without initial GC bridging) at selected time points (12, 18 and 24 months from baseline). Secondary outcomes were the mean oral GC cumulative dose from the moment the bridging schedule had ended (this same timepoint was chosen for the comparator arm of that study) until 24 months after baseline (ie, cumulative dose not including GC bridging), mean oral cumulative GC dose including GC bridging, continuous (≥3 months) use of GC (yes/no) at any time between end of bridging schedule and 24 months of follow-up, number of DMARD changes (adding a DMARD or switching between DMARDs, including csDMARDs and biological DMARDs (bDMARDs)), DAS28 over time and use of ≤5 mg/day (yes/no) as oral GC dose (within complete follow-up and during the period after bridging).

Statistical analysis

The outcomes for the individual studies separately are shown in online supplemental table 2. The individual data from the included trials were combined with one stage model mixed-effects regression analyses to compare the outcomes between patients who did and did not start GC bridging. Study arm was added as random effect to account for between-study arm differences. In case of dichotomous outcomes, mixed-effects logistic regression models were used resulting in ORs. For continuous outcomes, mixed-effects linear regression models were used resulting in coefficients. These coefficients display a difference in GC cumulative dose (mg) between the groups.

For the outcomes ‘number of DMARDs’ and ‘continuous GC use’, the time that patients were followed up was included as covariate to account for immortal time bias, as patients who had shorter follow-up time could not receive more or other DMARDs or a continuous GC course anymore after their follow-up time

Table 1 Overview of the included study arms

	BeSt ²	COBRA ¹	CareRA ¹⁵
GC bridging study arms	Arm 3, initial combination therapy with GC	Combined treatment arm	Low-risk group, COBRA slim arm
Initial GC dose	60 mg/day (prednisone)	60 mg/day (prednisone)	30 mg/day (prednisone)
Tapering to maintenance	In 7 weeks to 7.5 mg/day	In 6 weeks to 7.5 mg/day	In 5 weeks to 5 mg/day
Planned end	From weeks 28 to 36 tapered to zero if DAS ≤2.4 for at least 6 months	From weeks 28 to 34 tapered to zero	From weeks 28 to 34 tapered to zero if DAS28 (CRP) ≤3.2
DMARD	MTX 7.5 mg/week, increased to 25 mg/week if DAS >2.4 after 3 months SSZ 2000 mg/day	MTX 7.5 mg/week SSZ 2000 mg/day	MTX 15 mg/week
Non-GC bridging arms	Arms 1 (sequential monotherapy) and Arm 2 (step up combination therapy) MTX 15 mg/week (increased to 25 mg/week if DAS >2.4 after 3 months)	Monotherapy arm, SSZ 2000 mg/day	Low-risk group, MTX tight step up arm MTX 15 mg/week

CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joints; DMARD, disease-modifying antirheumatic drug; GC, glucocorticoids; MTX, methotrexate; SSZ, sulfasalazine.

Table 2 Baseline characteristics of participants in trials starting oral GC bridging versus not starting bridging

	Started with GC bridging* (n=252)	Started without GC bridging† (n=373)
Age (baseline) mean±SD	52 (14)	53 (13)
Sex (female) (%)	68	67
DAS mean±SD	4.5 (0.9)	4.5 (0.9)
DAS28 mean±SD	5.9 (1.3)	5.9 (1.2)
RF positive (%)	62	61
ACPA positive (%)	48	57

*BeSt arm 3 (MTX, SSZ and GC bridging); COBRA arm combination therapy (MTX, SSZ and GC bridging); CareRA arm COBRA slim (MTX and GC bridging).
†COBRA arm monotherapy (SSZ); BeSt arm 2 (step up combination therapy); BeSt arm 1 (sequential monotherapy)—both starting with MTX monotherapy; CareRA arm MTX tight step up (MTX monotherapy).
ACPA, anticitrullinated protein antibodies; DAS28, Disease Activity Score based on 28 joints; GC, glucocorticoids; MTX, methotrexate; RF, rheumatoid factor; SSZ, sulfasalazine.

had ended. To investigate DAS28 over time, we included an interaction term between treatment group (started or not started with GC bridging) and time (as categorical variable).

The CareRA study arms included patients with RA with a low risk for a bad prognosis (online supplemental figure 1). We used the same algorithm to identify low-risk and high-risk patients in the BeSt and the COBRA studies. The identified high-risk patients were subsequently used in a sensitivity analysis to evaluate if this subgroup showed different results. Missingness in the data was low (<5%) and therefore no data imputation technique was applied.¹⁶ Statistical analyses were performed with Stata SE V.16.1 (StataCorp, College Station, Texas, USA).

RESULTS

In total, 625 patients were included for these analyses, of whom 252 (40.3%) were treated in a study arm that started with GC bridging. Baseline characteristics were comparable between the groups with/without initial GC bridging, most patients were female (67%), the mean age was 52 years and the mean baseline DAS and DAS28 (both based on erythrocyte sedimentation rate) were high (table 2). Furthermore, the majority of patients had tested positive for rheumatoid factor and/or anticitrullinated protein antibodies.

The proportion of patients using oral GC relative to the number of patients in follow-up at that moment is displayed in figure 1. Per protocol, initial GC use was high in the group that started with GC bridging. At the first evaluation point after the planned endings of the bridging schedules (T=12 months), significantly more patients in the GC bridging group (21%) used GC than in the non-GC bridging group (6%) but at the subsequent time points, GC use was not significantly different between the groups, although there were numerical differences.

The end of GC bridging was planned by protocol and in two of the three studies this was dependent on achieving the treatment target. Of the patients from the GC bridging group who used GC at T=12 months, 77% had restarted GC after bridging had first ended and 23% had not yet stopped but still used GC after the initial planned end of bridging (if disease activity had allowed). When we evaluated the oral GC dose (≤ 5 mg or > 5 mg) related to all visits at which oral GC were used and GC dose was non-missing, it appeared that after the period of bridging until 2 years of follow-up comparable proportions of both groups were using ≤ 5 mg as daily dose ($p=0.30$, online supplemental table 3).

The GC bridging group had a significantly higher risk to use GC at the 12 months timepoint (OR 3.27 (95% CI 1.06 to




Figure 1 Percentage of patients on glucocorticoids (GC) treatment over time (in months) for the group that started with GC bridging initially (red) and the group that did not (blue). Asterisk (*) indicates significant result from the mixed-effects regression analyses performed for 12, 18 and 24 months. Braces below the x-axis indicate the duration of the intended bridging periods and the analysis period, for exact bridging periods see table 1.

10.08)) compared with non-GC bridging group, but it decreased over time and was no longer statistically significant at 18 and 24 months after baseline (OR 1.60 (95% CI 0.46 to 5.60) and OR 1.70 (95% CI 0.58 to 4.97), respectively). The cumulative dose after the planned bridging schedules did not differ significantly between the two groups (264 mg (95% CI -69 to 597)), but of course, when the bridging schedules were included, there was a significantly higher cumulative dose in the GC bridging group (2400 mg (95% CI 1400 to 3400)). This can be translated to an average difference of 3 mg/day for 2 years compared with the non-GC bridging group.

Furthermore, patients in the GC bridging group had a significantly higher risk of using GC for ≥ 3 months at any time between the end of bridging schedule and t=24 months (OR 3.11 (95% CI 1.94 to 4.98)). The incidence rate ratio (IRR) for number of DMARD changes was significantly lower for the GC bridging group (IRR 0.59 (95% CI 0.38 to 0.94)).

Mean DAS28 decrease over time was more rapid in the first 6 months in the GC bridging group (interaction term: $p<0.001$, figure 2). At later timepoints, after the planned end of bridging, there was no statistically significant difference anymore between the groups.

Sensitivity analysis

For the sensitivity analysis, 478 patients were available after excluding the 'low-risk' patients from the CareRA, BeSt and COBRA studies (table 3). The results were comparable with slightly larger effect estimates for the 'high-risk' patients only, but the IRR for occurrence of DMARD changes was no longer significantly different, although the IRR remained almost identical.

DISCUSSION

In this IPD meta-analysis on 2 years data from three RCTs that compared study arms starting with csDMARDs with or without initial GC bridging, we found that the proportion of patients using GC and the cumulative GC dose after t=12 months were similar between GC bridgers and non-GC bridgers. Also, we confirmed that bridgers achieved low disease activity




Figure 2 Mean DAS28 (data from linear mixed model) over time, estimated over 24 months. Predictive margins are depicted with 95% CIs as error bars. An asterisk (*) indicates significant result from the linear mixed model analysis. DAS28, Disease Activity Score based on 28 joints; GC, glucocorticoids.

significantly earlier than non-bridgers. After the end of the initial bridging schemes, bridgers and non-bridgers had similar DAS28 over time, but non-bridgers had more DMARD changes. In these relatively old trials, initially high dosed and long (on average 35 weeks) bridging schedules were used. Patients could by protocol restart or continue GC if the study treatment target was lost during or after tapering. At t=12 months, this resulted in 21% of patients in the bridgers group using GC compared with 6% of the non-bridgers, who had started GC following the allocated first csDMARD treatment. GC bridging resulted in a 2400 mg higher cumulative GC dose in the bridgers compared with the non-bridgers over the total follow-up of 2 years (including the bridging period).

Whether or not to start treatment for patients with RA including GC bridging is the theme of an ongoing international discussion, weighing the balance between benefits and harms. GC use has been associated with adverse effects, particularly

in high and/or prolonged doses. However, there are limited data about (long-term) adverse events, particularly medicinally unpreventable or untreatable adverse effects, associated with short-term GC use (ie, bridging) in patients with early RA. The weighing of the benefits and harms of GC (bridging) in combination with limited evidence on this subject has led to different international recommendations regarding GC bridging.⁸ The EULAR recommendations (2022 update)⁹ included a recommendation stating that short-term GC bridging in the first line of treatment should be considered, but the updated ACR recommendations (2021 update) advised, conditionally, not to use GC bridging at all, on the basis that the benefits of short-term GC do not outweigh the risk that GC initiation will lead to continued use with associated toxicity.¹⁰ In a recent SLR, we showed that few trials and no observational cohorts have been published on the successful discontinuation of initial GC bridging therapy in patients with newly diagnosed RA.¹⁴ We subsequently combined the raw data from the identified clinical trials that included an initial GC bridging arm in a previously published IPD meta-analysis, and found that only a minority of patients (with totals decreasing over time) continued GC after the planned initial bridging schedule.¹¹ Of course, in daily practice GC prescription does not always follow predefined strategies for GC discontinuation or restart that would be comparable to the included clinical trials in this study. In the current study, we tested whether initial GC bridging would affect whether patients would be more likely to (re)start GC over time, resulting in differences in cumulative GC dose over time, or more frequent DMARD changes, as it had been suggested that rapid suppression of disease activity may affect the disease course and later need for treatment changes. Numerical differences in GC use between a GC bridging and non-GC bridging group have been previously reported in a non-randomised prospective study.¹² Furthermore, the CareRA study already reported a numerically lower cumulative GC dose (including intramuscular and intra-articular GC injections) in low-risk patients in the GC bridging arm during the second year of follow-up.¹³ In the combined trials, we did not find such a difference in later GC use, but non-bridgers did need more DMARD changes and initially more time to achieve a low DAS28 than bridgers.

In discussions on risks and benefits of GC bridging, the focus is often on cumulative effects and long-term outcomes. It could be argued that with the introduction of more antirheumatic drugs and embedded in the notion of ‘treat-to-target’, the opportunities to achieve low disease activity or even remission later in the disease course have greatly increased, which, as we also show here, results in similar control of disease activity after longer follow-up. However, as shown again in this study, for non-bridgers this means prolonged disease activity while sometimes several treatment changes are required, each with their own potential adverse effects. Our studies and numerous RCTs (summarised in SLRs) with newer antirheumatic drugs have reported that the majority of patients starting treatment on monotherapy csDMARD (MTX) do not achieve remission or low disease activity in the first 3–6 months.^{12 17 18} We have confirmed here again a more rapid decrease in disease activity in the GC bridging arms. The importance of this early clinical response is supported by extensive data from literature as previous research has shown that early suppression of disease activity using GC bridging is associated with less DMARD changes (current study), less radiographic progression^{1 2} and this difference compared with non-bridgers was still statistically significant several years after bridging was stopped.⁷ Moreover, GC bridging is associated with less (permanent) productivity loss,^{19 20} less analgetic

Table 3 Mixed-effects regression analyses (rows indicate outcomes of separate models)

Outcome	Effect estimate and 95% CI	Effect estimate and 95% CI Sensitivity analysis (patients with a high risk for a bad prognosis from BeSt and COBRA)
GC use at 12 months	OR 3.3 (1.1 to 10.1)	OR 3.9 (1.0 to 15.0)
GC use at 18 months	OR 1.6 (0.5 to 5.6)	OR 2.0 (0.4 to 10.2)
GC use at 24 months	OR 1.7 (0.58 to 5.0)	OR 2.32 (1.0 to 5.5)
Mean cumulative dose at 24 months, excluding the bridging period	β 264 mg (−69 to 597)	β 356 mg (−48 to 762)
Mean cumulative dose at 24 months including the bridging period	β 2406 mg (1403 to 3408)	β 2935 mg (2348 to 3523)
Using GC ≥3 months*†	OR 3.1 (1.9 to 5.0)	OR 3.5 (2.2 to 5.5)
Occurrence of DMARD changes*†	IRR 0.6 (0.4 to 0.9)	IRR 0.6 (0.3 to 1.1)

Reference group: group that did not start GC bridging initially (for all analyses). Bold text indicates a significant result.
 *During the period in between the end of bridging and 24 months of time.
 †Also corrected for: time in study.
 DMARDs, disease-modifying antirheumatic drugs; GC, glucocorticoids; IRR, incidence rate ratio; β, coefficient.

use,²¹ less long-term fatigue²² and more long-term self-efficacy.²³ The psychological impact of rapid pain relief and restoration of function on the first treatment has rarely been reported and may require empathic reasoning. Whereas available (observational) studies generally agree on an increased risk of adverse events such as osteoporosis, infections and diabetes associated with GC use, results on a safe daily dose and/or duration are conflicting.⁸ Moreover, preventive measures (eg, anti-osteoporotic treatment) are not always taken into account and the risk of treatment is rarely balanced against the risk of inflammatory RA disease activity.^{24,25} Previous studies that did compare the effects of (suppression of) disease activity and GC use showed that the least bone mineral density decrease occurred in patients in which disease activity was well suppressed, even with GC, suggesting that well-controlled disease activity may outweigh the potentially detrimental effect on bone mineral density associated with GC use.²⁵ Most available data on GC toxicity are based on prolonged and/or high-dose GC use, in non-RA populations and/or on observational data with strong risk of confounding (bias) by indication and subject to the risk associated with the condition that was treated.^{26–29} Recently, the GLORIA trial demonstrated that the use of lower GC doses (≤ 5 mg/day prednisone equivalent) in elderly patients with established RA was effective in improving disease activity, functional ability and limiting radiographic progression, although associated with an increase of 24% in risk of at least one predefined AE of interest, which were mostly mild to moderate infections.³⁰ Data on short-term and long-term adverse events due to initial GC bridging therapy in RA are limited. RCTs are in general not sufficiently powered to compare (serious) adverse events, whereas observational studies generally do not focus on bridging schedules specifically and carry the risk of confounding by indication.^{8,31} The BeSt study has reported on the comparison of adverse effects of GC in year 1 between three arms who did not start GC bridging and one arm who did start GC bridging initially. They found slightly more cardiovascular events in the arm with GC bridging compared with the other arms and less bone mineral density loss.^{7,32} The COBRA study reported, for the first 56 weeks after start of treatment, on several expected adverse effects from GC: weight gain was significantly higher in the first 28 weeks in the GC bridging group compared with the SSZ monotherapy group, blood pressure remained stable in both groups and bone mineral density changes were also not significantly different between the bridgers and non-bridgers.¹ In the CareRA study, there was a comparable number of adverse events in the bridgers and non-bridgers, not further specified for GC-related adverse events.¹³ For the current analyses, IPD on adverse events were unavailable, which we recognise as a limitation of our study. The principle to ‘first do no harm’ could be easily translated into not prescribing GC bridging (or in fact any medication). However, treatment decisions always involve weighing benefits and risks, including the benefit of rapid suppression of disease activity versus the risk of unopposed and prolonged high disease activity, and the risk of potential (long-term) side effects of initial GC bridging. By design, the planned GC bridging schedules affected the comparison in cumulative GC doses between bridgers and non-bridgers. The initial GC dose used in the BeSt and COBRA studies (both 60 mg) and to a lesser extent the starting dose of the CareRA bridging arm (30 mg) were relatively high and the planned schedules of use relatively long, especially compared with current recommendations to stop within 3 months. The lower starting dose (30 mg) used in CareRA was found equally effective and comparable in terms of safety to the higher dose of 60 mg, in a direct comparison in the COBRA light study.³³ Our

previous IPD meta-analysis, which also included trials without a non-bridging treatment arm, showed that a lower initial GC bridging dose was associated with less GC use at 12 and 18 months after the planned end of bridging, and also with lower cumulative GC doses. Furthermore, it was suggested that parenteral GC bridging might be associated with less GC use during follow-up.¹¹ As yet, the long-term adverse events of these initial higher GC doses are unclear, and a comparison of the safety profile with shorter GC bridging schedules with lower cumulative GC doses, as proposed in current recommendations, is lacking. Therefore, it seems evident that there is a need for trials comparing lower and shorter GC bridging schedules with a previously tested regimen, such as COBRA slim, and with a treatment arm without GC bridging. Trying to avoid adverse effects of GC could affect achieving the benefits of GC. The recent CORRA trial showed that after a ‘COBRA light schedule’ that tapered to zero in 3 months, no radiological benefit could be shown.³⁴ For now, it remains unclear which is the best bridging schedule when balancing both safety and efficacy, and which (cumulative) dose of GC gives an increased risk of adverse events.

Alternatively, bridging with other rapid acting antirheumatic drugs may be considered. In the BeSt study, temporary treatment with infliximab (IFX) was at least as effective and safe as temporary treatment with GC.^{2,35} This is of course associated with higher drug costs, but this might be possibly offset by greater improvement in productivity.²⁰ The Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) study compared initial therapy with MTX and 2-monthly IFX to MTX with a single intravenous 250 mg dose of GC in patients with DMARD-naïve early RA and found no statistical superiority of the MTX plus IFX group compared with the GC group regarding radiographic progression and DAS remission.³⁶ Nor was there a statistical significant difference in additional GC requirement between the groups. An earlier RCT that evaluated MRI differences between MTX monotherapy, MTX plus 2-monthly 1000 mg intravenous GC and MTX plus 2-monthly IFX, after 1 year found less MRI erosion progression in the MTX plus IFX group than in the MTX plus IVIG group, but new erosions in previously undamaged joints were seen more often in the MTX plus IFX group.³⁷ More studies are needed for this comparison between MTX plus bDMARD and MTX plus GC bridging. For now, in daily practice individual deviations of previously trialled bridging schemes can only be considered per patient.

Patients in the GC bridging group were found to have fewer DMARD changes over time than patients in the non-GC bridging group, which may be cost saving and also more convenient for the individual patient. Possibly, patients in the GC bridging group changed DMARDs less often because the treatment protocols of the BeSt and COBRA studies required to prolong or restart GC (maintenance) dose before changing the csDMARD if, after GC tapering, the disease activity relapsed. This would tie in with our finding that at 12 months, patients in the GC bridging group used more GC than patients in the non-GC bridging group. The data showed that this use at 12 months was more often due to a recent restart (77%), than a reflection of a continuous course of GC, indicating a disease flare after the end of bridging while continuing csDMARD treatment. We speculate that GC bridging in general acts more rapidly than csDMARD monotherapy, and can mask a lack of efficacy of the csDMARD which becomes apparent only after GC discontinuation and requires a change of treatment. In patients from the non-GC bridging group with insufficient response, the need for DMARD treatment adaptation (not being masked by effective GC treatment) would have become apparent earlier in the process. In the BeSt study it was

shown that after failure on MTX, patients often also did not achieve low disease activity on the next csDMARDs; while in the meantime, radiographic damage progression occurred.³⁸ This may suggest that rapidly effective alternative treatments should be at hand, if GC use is limited to a short bridging period (eg, 3 months).

This analysis has several strengths and weaknesses. The combination of IPD from clinical trials in an IPD meta-analysis gives the possibility to analyse GC bridging in more detail than with the aggregated published data from the identified clinical trials only (a regular meta-analysis). However, the heterogeneity that exists between the studies can complicate combining these data, although this is partly compensated by adding 'study arm' as random effect. With our previously conducted SLR, 10 clinical trials were identified that included GC bridging.¹⁴ Only four of these trials had randomised between initial GC bridging and no initial GC bridging (comparator arms). Subsequently, investigators of three of these four trials agreed to share data for the current IPD meta-analysis. One³⁹ did not respond to our requests. As mentioned, individual data on adverse events were unavailable for the current analyses. Another limitation to our efforts to investigate the effects of initial GC bridging is the lack of available data from observational studies. Only clinical trials were included in this analysis. Clinical trials usually include a more homogeneous RA population than the RA population in clinical practice due to detailed inclusion and exclusion criteria, and therefore the results of such trials may be less generalisable to a daily practice RA population. As a rule, observational studies do reflect daily practice more (higher generalisability) but these carry the risk of 'confounding by indication'. In contrast to the BeSt and COBRA and perhaps more in resemblance to current daily practice, the CareRA study arms included in this analysis consisted of patients with RA with a low risk for a bad prognosis. We therefore have conducted a sensitivity analysis excluding the patients with a low risk for a bad prognosis from the CareRA, the BeSt and COBRA studies, which showed comparable results. However, there was a trend (larger effect estimates for the GC bridging group compared with the non-GC bridging group) towards more GC use when low-risk patients were excluded from the analysis, with also higher cumulative GC doses. Future studies, aided by online data collection, could focus on earlier effects of initial treatment and more tailored and responsive treatment adjustments over time. The bridging schedules of the included studies were all relatively long in contrast to the EULAR 2022 updated recommendations, in which a 3-month period is suggested/stated as a maximum duration.⁹ However, it is possible that the presence of a protocolised tapering schedule and predefined alternative treatment steps actually contributed to the success rates of tapering and stopping GC in the clinical trials. In daily practice, tapering GCs without such a tapering protocol might be more difficult. Patients often flare or otherwise feel worse after GC discontinuation, when it becomes apparent that csDMARDs are insufficiently effective.^{40–42} Switching to a bDMARD may prevent starting or going back to GC treatment. In our selected trials, we could not analyse the use of bDMARD and targeted synthetic DMARD between GC bridgers and non-GC bridgers as the first 2 years of the COBRA study did not include such medications.

To conclude, this IPD meta-analysis showed that in clinical trials about patients with newly diagnosed RA, initial GC bridging is associated with a more rapid clinical improvement and fewer DMARD changes compared with non-GC bridging, without apparent greater risk to continue GC use beyond 12 months. Future research should focus on finding the optimal

bridging strategy in early RA, including the best dose and duration, route of drug administration and possibly even type of medication, carefully balanced against the risk of adverse events.

Twitter Sytske Anne Bergstra @SytskeAnne

Contributors All authors contributed to the analysis plan. MB, PV and CFA have provided the data. SAB, CFA and LvO analysed the data and drafted the manuscript and accept full responsibility for the work and/or the conduct of the study. SAB, CFA and LvO had access to the data and controlled the decision to publish. All authors revised the drafted manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests LvO, PHPdJ, RBML, JSS and TWJH declare no competing interests. MB: reports speaker fees from Novartis and Pfizer, and provided expert testimony for Celltrion. PV: holds the Pfizer Chair Early Rheumatoid Arthritis Management as well as the Galapagos Chair in RA at KU Leuven and received consultancy and/or speaker honoraria from AbbVie, Celltrion, Eli Lilly, Galapagos, Gilead, Nordic Pharma, Roularta and Sidekick Health within the last 24 months. SAB: received an ASPIRE grant from Pfizer. CFA: received study grants for BeSt and IMPROVED from Centocor (now Janssen) and AbbVie, respectively. PE: provided expert advice to AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Galapagos, Gilead, Janssen, MSD, Lilly, Novartis, Pfizer, Roche, Samsung. And clinical trials: AbbVie, BMS, Lilly, Novartis, Pfizer, Roche, Samsung. WL received study grants from Pfizer and consultancy speaker fees from Eli Lilly, Pfizer, Amgen, Galapagos and UCB.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Every clinical trial used in this individual patient data meta-analysis has been approved by the local ethics committee. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Lotte van Ouwkerk <http://orcid.org/0000-0001-8036-950X>

Patrick Verschuere <http://orcid.org/0000-0002-0340-3580>

Maarten Boers <http://orcid.org/0000-0002-6969-283X>

Paul Emery <http://orcid.org/0000-0002-7429-8482>

Pascal Hendrik Pieter de Jong <http://orcid.org/0000-0001-6628-6222>

Robert BM Landewé <http://orcid.org/0000-0002-0577-6620>

Willem Lems <http://orcid.org/0000-0002-6885-3953>

Tom WJ Huizinga <http://orcid.org/0000-0001-7033-7520>

Sytske Anne Bergstra <http://orcid.org/0000-0002-7136-5248>

REFERENCES

- Boers M, Verhoeven AC, Markuse HM, *et al*. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;350:309–18.
- Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, *et al*. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): A randomized, controlled trial. *Arthritis Rheum* 2008;58(2 Suppl):S126–35.
- de Jong PH, Hazes JM, Han HK, *et al*. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy: 1-year data of the tREACH trial. *Ann Rheum Dis* 2014;73:1331–9.
- ter Wee MM, den Uyl D, Boers M, *et al*. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional Etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. *Ann Rheum Dis* 2015;74:1233–40.
- Boers M, van Tuyl L, van den Broek M, *et al*. "Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis". *Ann Rheum Dis* 2013;72:406–9.

- 6 Stouten V, Westhovens R, Pazmino S, *et al.* Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the Carera trial *Ann Rheum Dis* 2023;82:e163.
- 7 Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, *et al.* The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the best study. *Ann Rheum Dis* 2011;70:1039–46.
- 8 Bergstra SA, Sepriano A, Kerschbaumer A, *et al.* Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2023;82:81–94.
- 9 Smolen JS, Landewé RBM, Bergstra SA, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying Antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2023;82:3–18.
- 10 Fraenkel L, Bathon JM, England BR, *et al.* American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol* 2021;73:1108–23.
- 11 van Ouwkerk L, Boers M, Emery P, *et al.* Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. *Ann Rheum Dis* 2022;82:468–75.
- 12 Verschuere P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. *Rheumatology (Oxford)* 2008;47:59–64.
- 13 Stouten V, Westhovens R, Pazmino S, *et al.* Effectiveness of different combinations of Dmards and glucocorticoid bridging in early rheumatoid arthritis: two-year results of Carera. *Rheumatology (Oxford)* 2019;58:2284–94.
- 14 van Ouwkerk L, Palmowski A, Nevins IS, *et al.* Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. *Ann Rheum Dis* 2022;81:937–43.
- 15 Verschuere P, De Cock D, Corluy L, *et al.* Methotrexate in combination with other Dmards is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the Carera trial. *Ann Rheum Dis* 2015;74:27–34.
- 16 Jakobsen JC, Gluud C, Wetterslev J, *et al.* When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with Flowcharts. *BMC Med Res Methodol* 2017;17:162.
- 17 Kerschbaumer A, Sepriano A, Smolen JS, *et al.* Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2020;79:744–59.
- 18 Kerschbaumer A, Sepriano A, Bergstra SA, *et al.* Efficacy of synthetic and biological Dmards: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2023;82:95–106.
- 19 de Jong PHP, Hazes JM, Buisman LR, *et al.* Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. *Rheumatology (Oxford)* 2016;55:2138–47.
- 20 van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF, *et al.* Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum* 2009;61:291–9.
- 21 Pazmino S, Boonen A, De Cock D, *et al.* Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: Subanalysis of the Carera randomised controlled trial. *RMD Open* 2021;7:e001615.
- 22 Doumen M, Pazmino S, Bertrand D, *et al.* Longitudinal Trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response. *Ann Rheum Dis* 2022;81:1385–91.
- 23 Doumen M, De Cock D, Pazmino S, *et al.* Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis. *Arthritis Res Ther* 2021;23:285.
- 24 Wiebe E, Huscher D, Schaumburg D, *et al.* Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. *Ann Rheum Dis* 2022;81:1313–22.
- 25 Dirven L, Güler-Yüksel M, de Beus WM, *et al.* Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial. *Arthritis Care Res* 2011;63:1691–9.
- 26 Sarnes E, Crofford L, Watson M, *et al.* Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. *Clin Ther* 2011;33:1413–32.
- 27 Gurwitz JH, Bohn RL, Glynn RJ, *et al.* Glucocorticoids and the risk for initiation of Hypoglycemic therapy. *Arch Intern Med* 1994;154:97–101.
- 28 Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med* 2004;141:764–70.
- 29 Curtis JR, Westfall AO, Allison J, *et al.* Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum* 2006;55:420–6. 10.1002/art.21984 Available: <http://doi.wiley.com/10.1002/art.v55%3A3>
- 30 Boers M, Hartman L, Opris-Belinski D, *et al.* Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. *Ann Rheum Dis* 2022;81:925–36.
- 31 Courvoisier DS, Lauper K, Kedra J, *et al.* EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. *Ann Rheum Dis* 2022;81:780–5.
- 32 Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, *et al.* Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis* 2008;67:823–8.
- 33 den Uyl D, ter Wee M, Boers M, *et al.* A non-inferiority trial of an attenuated combination strategy ("COBRA-light") compared to the original COBRA strategy: clinical results after 26 weeks. *Ann Rheum Dis* 2014;73:1071–8.
- 34 Krause D, Mai A, Klaassen-Mielke R, *et al.* The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. *Arthritis Rheumatol* 2022;74:1628–37.
- 35 Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, *et al.* Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406–15.
- 36 Nam JL, Villeneuve E, Hensor EMA, *et al.* Remission induction comparing Infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). *Ann Rheum Dis* 2014;73:75–85.
- 37 Durez P, Malghem J, Nzeusseu Toukap A, *et al.* Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with Infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis Rheum* 2007;56:3919–27.
- 38 van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, *et al.* Limited efficacy of conventional Dmards after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis* 2007;66:1356–62.
- 39 Hua L, Du H, Ying M, *et al.* Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial. *Medicine (Baltimore)* 2020;99:e20824e20824.
- 40 Maassen JM, Dos Santos Sobrin R, Bergstra SA, *et al.* Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the best and IMPROVED studies. *Ann Rheum Dis* 2021;80:1124–9.
- 41 Adami G, Fassio A, Rossini M, *et al.* Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying Antirheumatic drugs (bdMARDs). *RMD Open* 2023;9:e002792.
- 42 Xie W, Huang H, Zhang Z. Dynamic characteristics and predictive profile of glucocorticoids withdrawal in rheumatoid arthritis patients commencing glucocorticoids with csDMARD: A real-world experience. *Rheumatol Ther* 2023;10:405–19.